OOIR: Observatory of International Research

Papers

(The H4-Index of Biochemical Pharmacology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The growth of siRNA-based therapeutics: Updated clinical studies	300
Detection of Viral Infections by Innate Immunity	250
Sleep timing, chronotype and social jetlag: Impact on cognitive abilities and psychiatric disorders	123
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery	115
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro	108
White adipose tissue dysfunction in obesity and aging	105
Targeting tumor-associated macrophages as an antitumor strategy	104
P2X7 receptor and the NLRP3 inflammasome: Partners in crime	100
Cisplatin in cancer treatment	97
Polo-like kinase 1 (PLK1) signaling in cancer and beyond	96
Therapeutic potential of targeting mitochondrial dynamics in cancer	95
Obesity I: Overview and molecular and biochemical mechanisms	88
Obesity II: Establishing causal links between chemical exposures and obesity	85
Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action	81
Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches	80
The relevance of daylight for humans	79
Mechanisms of ketamine and its metabolites as antidepressants	79
Minocycline promotes functional recovery in ischemic stroke by modulating microglia polarization through STAT1/STAT6 pathways	76
Ferroptosis and its potential as a therapeutic target	73
Recent progress on targeting ferroptosis for cancer therapy	72
Applications and evolution of melittin, the quintessential membrane active peptide	68
Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms	65
Drug affinity responsive target stability (DARTS) accelerated small molecules target discovery: Principles and application	65
Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance	64
Role of glutamate excitotoxicity and glutamate transporter EAAT2 in epilepsy: Opportunities for novel therapeutics development	63

Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation	56
Targeting immunosuppression by TGF-β1 for cancer immunotherapy	55
Antisense drug discovery and development technology considered in a pharmacological context	55
TGF-β1-activated cancer-associated fibroblasts promote breast cancer invasion, metastasis and epithelial-mesenchymal transition by autophagy or overexpression of FAP-α	55
Regulation of IRF3 activation in human antiviral signaling pathways	55
Targeted therapy for breast cancer: An overview of drug classes and outcomes	55
Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics	54
Vitamin D and the risk for cancer: A molecular analysis	54
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking	53
History of ectonucleotidases and their role in purinergic signaling	53
Molecular pharmacology of P2Y receptor subtypes	53
Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective	52
Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs	51
The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations	51
Amino acid metabolism, transport and signalling in the liver revisited	51
Parathyroid hormone and its related peptides in bone metabolism	50
Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential	50
A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy	47
Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors	47
Insights into the role of GPX3, a highly efficient plasma antioxidant, in cancer	47
Tumor Cells-derived exosomal CircRNAs: Novel cancer drivers, molecular mechanisms, and clinical opportunities	47
Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response	47
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients	47
Aryl hydrocarbon receptor: Its roles in physiology	47